PURPOSE: New multimodality treatment approaches for prostate cancer require multidisciplinary management of patients. We aimed to assess the current practices of multidisciplinarity and their possible implications in treatment management in Switzerland. METHODS: In a survey, urologists and medical oncologists in Switzerland were asked to include at least 25 or 15 consecutive patients with the diagnosis of prostate cancer, respectively. Information about treatment patterns and multidisciplinary parameters of these patients was collected retrospectively. RESULTS: Thirty-seven urologists and 20 oncologists from the French- and German-speaking parts of Switzerland representing 7 out of 11 non-university tertiary centres and 20/10 % of all office-based urologists/oncologists in Switzerland collected data on 1,184 patients. Sixty-five percent of the office-based (16/24 urologists; 6/10 oncologists) and 95 % of the hospital-based (10/11 urologists; 8/8 oncologists) physicians participate in multidisciplinary tumour boards (MTBs). However, only 1.5 % of patients with a new diagnosis of prostate cancer (13 of 883) are discussed at a MTB. Overall, second opinions at diagnosis are requested in 23 % of patients, mainly from radiation oncologists (8.4 %) or fellow urologists (7.4 %). Second opinions are more often requested by urologists who participate at MTBs and in case of advanced stage. CONCLUSIONS: Participation at MTBs is high among Swiss urologists and oncologists in private practice and at non-university tertiary centers. In spite of that only a small minority of patietns with prostate cancer are presented at MTBs.
PURPOSE: New multimodality treatment approaches for prostate cancer require multidisciplinary management of patients. We aimed to assess the current practices of multidisciplinarity and their possible implications in treatment management in Switzerland. METHODS: In a survey, urologists and medical oncologists in Switzerland were asked to include at least 25 or 15 consecutive patients with the diagnosis of prostate cancer, respectively. Information about treatment patterns and multidisciplinary parameters of these patients was collected retrospectively. RESULTS: Thirty-seven urologists and 20 oncologists from the French- and German-speaking parts of Switzerland representing 7 out of 11 non-university tertiary centres and 20/10 % of all office-based urologists/oncologists in Switzerland collected data on 1,184 patients. Sixty-five percent of the office-based (16/24 urologists; 6/10 oncologists) and 95 % of the hospital-based (10/11 urologists; 8/8 oncologists) physicians participate in multidisciplinary tumour boards (MTBs). However, only 1.5 % of patients with a new diagnosis of prostate cancer (13 of 883) are discussed at a MTB. Overall, second opinions at diagnosis are requested in 23 % of patients, mainly from radiation oncologists (8.4 %) or fellow urologists (7.4 %). Second opinions are more often requested by urologists who participate at MTBs and in case of advanced stage. CONCLUSIONS: Participation at MTBs is high among Swiss urologists and oncologists in private practice and at non-university tertiary centers. In spite of that only a small minority of patietns with prostate cancer are presented at MTBs.
Authors: Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096
Authors: Riccardo Valdagni; Peter Albers; Chris Bangma; Lawrence Drudge-Coates; Tiziana Magnani; Clare Moynihan; Chris Parker; Kathy Redmond; Cora N Sternberg; Louis Denis; Alberto Costa Journal: Eur J Cancer Date: 2010-12-01 Impact factor: 9.162
Authors: Ann S Hamilton; Peter C Albertsen; Terri Kang Johnson; Richard Hoffman; Donna Morrell; Dennis Deapen; David F Penson Journal: BJU Int Date: 2010-08-24 Impact factor: 5.588
Authors: Leonard G Gomella; Jianqing Lin; Jean Hoffman-Censits; Patricia Dugan; Fran Guiles; Costas D Lallas; Jaspreet Singh; Peter McCue; Timothy Showalter; Richard K Valicenti; Adam Dicker; Edouard J Trabulsi Journal: J Oncol Pract Date: 2010-11 Impact factor: 3.840
Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Mark S Soloway; Cynthia T Soloway; Ahmed Eldefrawy; Kristell Acosta; Bruce Kava; Murugesan Manoharan Journal: Eur Urol Date: 2010-08-20 Impact factor: 20.096
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Matthew R Cooperberg; Jeanette M Broering; Mark S Litwin; Deborah P Lubeck; Shilpa S Mehta; James M Henning; Peter R Carroll Journal: J Urol Date: 2004-04 Impact factor: 7.450
Authors: Peter Rüesch; René Schaffert; Susanne Fischer; Deb Feldman-Stewart; Robin Ruszat; Peter Spörri; Markus Zurkirchen; Hans-Peter Schmid Journal: Support Care Cancer Date: 2013-11-28 Impact factor: 3.603